Oluyemi Okupe Sells 9,067 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 9,067 shares of Hims & Hers Health stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $30.34, for a total transaction of $275,092.78. Following the completion of the sale, the chief financial officer directly owned 91,617 shares of the company’s stock, valued at approximately $2,779,659.78. The trade was a 9.01% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, January 5th, Oluyemi Okupe sold 9,070 shares of Hims & Hers Health stock. The shares were sold at an average price of $33.79, for a total transaction of $306,475.30.
• On Monday, December 22nd, Oluyemi Okupe sold 23,090 shares of Hims & Hers Health stock. The shares were sold at an average price of $35.72, for a total transaction of $824,774.80.
• On Monday, November 17th, Oluyemi Okupe sold 23,187 shares of Hims & Hers Health stock. The stock was sold at an average price of $36.81, for a total transaction of $853,513.47.
• On Monday, November 17th, Oluyemi Okupe sold 23,187 shares of Hims & Hers Health stock. The shares were sold at an average price of $36.81, for a total transaction of $853,513.47.

Hims & Hers Health Price Performance

HIMS stock opened at $30.51 on Friday. The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.64 and a current ratio of 1.88. The business has a 50-day simple moving average of $35.10 and a two-hundred day simple moving average of $45.21. The company has a market capitalization of $6.95 billion, a P/E ratio of 56.50, a price-to-earnings-growth ratio of 4.90 and a beta of 2.37. Hims & Hers Health, Inc. has a 52-week low of $23.97 and a 52-week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, November 3rd. The company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). The company had revenue of $598.98 million during the quarter, compared to the consensus estimate of $578.99 million. Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The firm’s revenue for the quarter was up 49.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.32 EPS. Research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health declared that its board has initiated a share buyback program on Monday, November 17th that permits the company to buyback $250.00 million in outstanding shares. This buyback authorization permits the company to repurchase up to 3% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

Analysts Set New Price Targets

A number of research firms recently weighed in on HIMS. Barclays started coverage on shares of Hims & Hers Health in a research report on Monday, December 8th. They set an “overweight” rating and a $48.00 price target on the stock. UBS Group set a $32.00 price objective on shares of Hims & Hers Health in a research note on Tuesday, November 4th. Wall Street Zen downgraded Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Zacks Research lowered Hims & Hers Health from a “hold” rating to a “strong sell” rating in a report on Monday. Finally, KeyCorp started coverage on Hims & Hers Health in a report on Tuesday, October 21st. They set a “sector weight” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, nine have assigned a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $44.54.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of HIMS. Quent Capital LLC purchased a new position in Hims & Hers Health in the third quarter valued at approximately $28,000. Binnacle Investments Inc purchased a new stake in Hims & Hers Health in the third quarter worth $28,000. Virtus Advisers LLC bought a new stake in shares of Hims & Hers Health in the second quarter valued at $26,000. Quaker Wealth Management LLC purchased a new position in shares of Hims & Hers Health during the 2nd quarter valued at $29,000. Finally, Bessemer Group Inc. grew its stake in shares of Hims & Hers Health by 105.8% during the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after acquiring an additional 312 shares during the period. 63.52% of the stock is owned by institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.